Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.

@article{Delbaldo2004BenefitsOA,
  title={Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.},
  author={Catherine Delbaldo and Stefan Michiels and Nathalie Syz and J Soria and Thierry Le Chevalier and Jean-Pierre Pignon},
  journal={JAMA},
  year={2004},
  volume={292 4},
  pages={470-84}
}
CONTEXT Randomized trials have demonstrated that adding a drug to a single-agent or to a 2-agent regimen increased the tumor response rate in patients with advanced non-small-cell lung cancer (NSCLC), although its impact on survival remains controversial. OBJECTIVE To evaluate the clinical benefit of adding a drug to a single-agent or 2-agent chemotherapy regimen in terms of tumor response rate, survival, and toxicity in patients with advanced NSCLC. DATA SOURCES AND STUDY SELECTION Data… CONTINUE READING
95 Citations
1 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 95 extracted citations

References

Publications referenced by this paper.

Benefits of adding a drug to a single - agent or a 2 - agent chemotherapy regimen in advanced non - small - cell lung cancer : a meta - analysis

  • P PignonJ

Similar Papers

Loading similar papers…